Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Irreversibly and covalently binds the mutant cysteine in KRAS G12C, locking the mutant protein in its inactive state and preventing downstream signalling without inhibiting wild-type KRAS.
Indications / reported uses
As monotherapy for adults with KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer after at least one prior systemic therapy (accelerated approval; continued approval may depend on confirmatory evidence)
In combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Adagrasib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Adagrasib Permitted Daily Exposure (PDE) report (the Adagrasib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Adagrasib Occupational Exposure Limit (OEL) report (the Adagrasib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.